Cytodyn INC Form 4 insider transactions

CytoDyn Inc. director Tanya Durkee Urbach received a grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly through March 2027.

CytoDyn Inc. Director Stephen M. Simes was granted 574,385 non-qualified stock options at an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc. Director Lishomwa C Ndhlovu received an annual grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc.'s CEO, Jacob P. Lalezari, was granted 4,874,691 non-qualified stock options with an exercise price of $0.28, vesting over several years.

CytoDyn Inc.'s Chief Financial Officer, Robert E. Hoffman, was granted 4,874,691 non-qualified stock options with an exercise price of $0.28.

CytoDyn Inc. director Ryan Dunlap was granted 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc. Director Karen J Brunke was granted 574,385 non-qualified stock options at an exercise price of $0.28, vesting over 12 months.

CytoDyn Inc.'s Chief Legal Officer, Tyler Blok, was granted 3,249,794 non-qualified stock options with an exercise price of $0.28, vesting over several years.

CytoDyn's Chief Financial Officer, Robert E. Hoffman, was granted 1,000,000 non-qualified stock options on May 15, 2025, according to a Form 4 filing.

Director Tanya Durkee Urbach of CytoDyn Inc. was granted non-qualified stock options for 800,000 shares on October 28, 2024, as part of her annual compensation.

Stephen Simes, a director at CytoDyn Inc., was granted stock options for 800,000 shares as part of his annual compensation for fiscal year 2025.

Director Lishomwa C Ndhlovu of CytoDyn Inc. was granted 800,000 non-qualified stock options on October 28, 2024, as part of the annual grant for fiscal year 2025.

CytoDyn's CEO, Jacob P. Lalezari, was granted 3,000,000 non-qualified stock options on October 28, 2024, as part of his annual compensation for fiscal year 2025.

Director Ryan Dunlap receives a stock option grant for 800,000 shares of CytoDyn Inc. common stock.

Director Karen Brunke reports the grant of non-qualified stock options for 800,000 shares of CytoDyn Inc. common stock.

Tyler Blok, Chief Legal Officer of CytoDyn Inc., was granted non-qualified stock options for 1,250,000 shares on October 28, 2024, as part of his annual grant for fiscal year 2025.

CytoDyn's CEO, Jacob Lalezari, was granted 3,000,000 non-qualified stock options on March 7, 2024, vesting monthly over four years.